The presence of circulating tumor DNA in early-stage triple-negative breast cancer helped predict the risk of recurrence in women who had undergone surgery after neoadjuvant chemotherapy, a study found.
The phase III E1912 clinical study showed superior progression-free survival and overall survival in patients with chronic lymphocytic leukemia new to treatment.
TOURMALINE-AL1 trial, a phase III, randomized clinical trial evaluating the effect of Ninlaro (ixazomib) in combination with dexamethasone, did not meet the first of the two primary endpoints of significant improvement in overall hematologic response in patients with relapsed or refractory systemic light-chain amyloidosis.
MacroGenics Inc. has presented updated results from the phase III SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies.
Keytruda (pembrolizumab) showed improvements in overall survival, progression-free survival and objective response rate as monotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer whose tumors expressed PD-L1 (tumor proportion score [TPS] ≥1%), regardless of KRAS mutational status.
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients' bodies, a study led by Dana-Farber Cancer Institute researchers suggests.
On December 10, 2019, Dr. William G. Kaelin, Jr, Sir Peter J. Ratcliffe, and Dr. Gregg L. Semenza officially received the title of Nobel Laureate in Medicine.
The Senate Dec. 12 voted 72-18 to confirm Stephen Hahn as FDA commissioner.
Even moderate levels of alcohol consumption appear to be associated with a higher risk of some cancers—including cancers of the female breast—as well as adverse cardiovascular health effects, NCI researchers wrote in JAMA.
Memorial Sloan Kettering Cancer Center Dec. 10 marked the opening of David H. Koch Center for Cancer Care, a $1.5 billion cancer treatment facility, a 750,000-square-foot building which will open for patient care next month.
